Year All202620252024 Jul 20, 2026 Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer Jul 17, 2026 Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts Jul 06, 2026 Kalaris Appoints Laurie Keating to Board of Directors Jun 23, 2026 Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling Jun 12, 2026 Kalaris to Present at Clinical Trials at the Summit 2026 May 12, 2026 Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates Mar 17, 2026 Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates Jan 28, 2026 Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
Jul 17, 2026 Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Jun 23, 2026 Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
